William Blair downgraded Nkarta from Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | Outperform → Mkt Perform | William Blair | |
| 10/9/2024 | $14.00 | Buy | Rodman & Renshaw |
| 8/14/2024 | $16.00 | Outperform → Strong Buy | Raymond James |
| 3/22/2024 | $13.00 → $16.00 | Strong Buy → Outperform | Raymond James |
| 12/22/2022 | Outperform → Perform | Oppenheimer | |
| 10/10/2022 | $25.00 | Buy | Canaccord Genuity |
| 7/28/2022 | $26.00 | Buy | Needham |
| 7/18/2022 | $30.00 | Outperform | SVB Leerink |
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmu
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWI
William Blair downgraded Nkarta from Outperform to Mkt Perform
Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00
Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00
10-Q - Nkarta, Inc. (0001787400) (Filer)
8-K - Nkarta, Inc. (0001787400) (Filer)
DEFA14A - Nkarta, Inc. (0001787400) (Filer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
SC 13G - Nkarta, Inc. (0001787400) (Subject)
SC 13G/A - Nkarta, Inc. (0001787400) (Subject)
SC 13G/A - Nkarta, Inc. (0001787400) (Subject)
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)